PPT-Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)

Author : zane419 | Published Date : 2024-09-18

Study 105 Atazanavir Cobicistat or Ritonavir TDFFTC Phase 2 Study 105 Study Design Source Elion R et al AIDS 20112518816 Background Randomized partially placebocontrolled

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Atazanavir + [Cobicistat or Ritonavir] +..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2): Transcript

Study 105 Atazanavir Cobicistat or Ritonavir TDFFTC Phase 2 Study 105 Study Design Source Elion R et al AIDS 20112518816 Background Randomized partially placebocontrolled doubleblind phase 2 trial to compare the safety and efficacy of cobicistat and ritonavir as pharmacokinetic enhancers administered with atazanavir and fixeddose tenofovir DFemtricitabine in treatmentnaïve adults with HIV infection. Fostemsavir. , . prodrug. of . temsavir. . (. attachment . inhibitor. ). AI438011 . Study. TAF (TFV . prodrug. ). Study . 292-0102. Study . 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. Source: Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. 3D . (Paritaprevir-Ritonavir-. Ombitasvir + Dasabuvir) + Ribavirin in GT1. . and Dasabuvir +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65.. An Update on Injectable . P. revention. Alex R Rinehart, PhD. Director, Global HIV Prevention Strategy. ViiV Healthcare. Cabotegravir LA (CAB LA) for PrEP. CAB is an investigational HIV integrase strand transfer inhibitor and analogue of dolutegravir. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles Prepared by: . Sophie . Woolston. , MD and David H. Spach, MD. Last . Updated: . November 18, 2014. 3D. Background and Dosing. 3D (. Paritaprevir. -Ritonavir-. Ombitasvir. + . Dasabuvir. ). 3D (. Paritaprevir. GS-US-216-0114. . Gallant JE. JID 2013;208:32-9. GS-US-216-0114. Design. Objective. Non inferiority of COBI compared with RTV at W48: % HIV RNA < 50 c/mL . by intention to treat, snapshot analysis (lower limit for the 95% CI for the difference = -12%, 95% power). AI424-043 . Study. Atazanavir vs. Lopinavir-ritonavir in Previous PI Failure . AI424-043. : Study Design. Source: . Cohen C, et al. . Curr Med Res Opin. . 2005;21:. 1683-92.. Atazanavir 400 mg once daily + 2 NRTIs. Ombitasvir + . Dasabuvir) +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65.. iPrEx. Trial . Substudy. TDF-FTC versus Placebo as HIV . PrEP. for Transgender Women. iPrEx. . Substudy. : Study Design. Source: Deutsch MB, et al. Lancet HIV. 2015;2:e512-9.. Background. : . Subgroup analysis of the . Andrew Hill, Francois Venter, Eric . Delaporte. , . Simiso. Sokhela, Charles . Kouanfack. , . Michelle Moorhouse. , Kaitlyn McCann, Bryony Simmons. , . Alexandra . Calmy. Disclosures. Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Johnson and Johnson, Sanofi, Pfizer, ViiV Healthcare, Mylan and Southern African HIV Clinicians Society. NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC. NEAT001/ANRS143: Study Design. Source: . Raffi. F, et al. Lancet. 2014;384:1942-51. .. Darunavir + Ritonavir QD. + Raltegravir BID .

Download Document

Here is the link to download the presentation.
"Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.